Assessment of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy Using Clonidine and Yohimbine Challenges
Data Collection
Metabolic Diseases+9
+ Nutritional and Metabolic Diseases
+ Pathologic Processes
Summary
Study start date: November 1, 1999
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: Antihypertensives are held, beginning 3 days before the first study day. An oral challenge is administered as follows: clonidine on day 1, yohimbine on day 2. The order of administration is reversed in alternate subjects. Timed measurements of norepinephrine, glycerol, and free fatty acids follow each challenge. Structural gene sequencing is evaluated for each participant.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.12 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Clinical diagnosis of regional lipoatrophy Control subjects: Women aged 18 to 65 Weight 90% to 150% of ideal No significant acute or chronic illness --Patient Characteristics-- Negative pregnancy test required of fertile women
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
University of Texas Medical Branch
Galveston, United StatesOpen University of Texas Medical Branch in Google Maps